, , 2020.
, Primary Central Nervous System Tumors: Pathogenesis and Therapy, 2011.
, The Lancet, vol.363, pp.1535-1543, 2004.
The outcome of patients with surgically treated meningioma in England: 1999-2013. A cancer registry data analysis, Br. J. Neurosurg, vol.33, pp.641-647, 2019. ,
Tumeurs primitives du système nerveux central -Classifications histologique et topographique, et épidémiologie, pp.17-83172, 2018. ,
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary, Acta Neuropathol. (Berl.), vol.131, pp.803-820, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01479018
Classification of meningiomas-advances and controversies. Chin, Clin. Oncol, vol.6, p.3, 2017. ,
Meningiomas With Rhabdoid Features Lacking Other Histologic Features of Malignancy: A Study of 44 Cases and Review of the Literature, J. Neuropathol. Exp. Neurol, vol.75, pp.44-52, 2016. ,
Epidemiology of meningiomas. A nationwide study of surgically treated tumours on French medico-administrative data, Cancer Epidemiol, vol.58, pp.63-70, 2019. ,
Racial Differences in Disease Presentation and Management of Intracranial Meningioma, J. Neurol. Surg. Part B Skull Base, vol.80, pp.555-561, 2019. ,
, Epidemiology of meningiomas. Neurochirurgie, vol.64, pp.5-14, 2018.
An overview of meningiomas, Future Oncol, vol.14, pp.2161-2177, 2018. ,
, Survival and Prognostic Predictors of Anaplastic Meningiomas. World Neurosurg, vol.131, pp.321-328, 2019.
Relationship between tumor location, size, and WHO grade in meningioma, Neurosurg. Focus, vol.44, p.4, 2018. ,
, Metastatic Atypical and Anaplastic Meningioma: A Case Series and Review of the Literature. World Neurosurg, vol.101, pp.47-56, 2017.
EANO guidelines for the diagnosis and treatment of meningiomas, Lancet Oncol, vol.17, pp.383-391, 2016. ,
Spectrochemical differentiation of meningioma tumours based on attenuated total reflection Fourier-transform infrared (ATR-FTIR) spectroscopy, Anal. Bioanal. Chem, 2019. ,
Diagnostic challenges in meningioma, Neuro-Oncol, vol.19, pp.1588-1598, 2017. ,
,
, Expression in Meningioma Patients: A Meta-Analysis, Crit. Rev. Eukaryot. Gene Expr, vol.29, pp.141-150, 2019.
Correlation of Peritumoral Brain Edema with Morphological Characteristics and Ki67 Proliferative Index in Resected Intracranial Meningiomas, Acta Clin. Croat, 2019. ,
Octreotide therapy in meningiomas: in vitro study, clinical correlation, and literature review, J. Neurosurg, vol.127, pp.660-669, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01478922
The application of fluorescence techniques in meningioma surgery-a review, Neurosurg. Rev, vol.42, pp.799-809, 2019. ,
Expression of vascular endothelial growth factor in human meningiomas and peritumoral brain areas, Ann. Clin. Lab. Sci, vol.38, pp.344-351, 2008. ,
Current and emerging principles in surgery for meningioma, Clin. Oncol, vol.6, pp.7-7, 2017. ,
Meningiomas: Overview and New Directions in Therapy, Semin. Neurol, vol.38, pp.112-120, 2018. ,
Benefits of re-do surgery for recurrent intracranial meningiomas, Sci. Rep, vol.10, p.303, 2020. ,
, , vol.1
Emerging Medical Treatments for Meningioma in the Molecular Era, Biomedicines, vol.6, p.86, 2018. ,
Historical benchmarks for medical therapy trials in surgery-and radiationrefractory meningioma: a RANO review, Neuro-Oncol, vol.16, pp.829-840, 2014. ,
Role of bevacizumab for treatment-refractory meningiomas: A systematic analysis and literature review, Surg. Neurol. Int, vol.9, p.133, 2018. ,
Pasireotide is more effective than octreotide, alone or combined with everolimus on human meningioma in vitro, Oncotarget, vol.8, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01731578
Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005, J. Clin ,
, Oncol. Off. J. Am. Soc. Clin. Oncol, vol.33, pp.4093-4098, 2015.
New molecular targets in meningiomas: the present and the future, Curr. Opin. Neurol, vol.31, pp.740-746, 2018. ,
Phosphatidylinositol 3-Kinase ?-Selective Inhibition With Alpelisib (BYL719) in PIK3CA -Altered Solid Tumors: Results From the First-in-Human Study, J. Clin. Oncol, vol.36, pp.1291-1299, 2018. ,
Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial, Clin. Cancer Res, vol.26, pp.552-557, 2020. ,
URL : https://hal.archives-ouvertes.fr/hal-02457059
Neurofibromatosis Type 2, J. Child Neurol, vol.32, pp.9-22, 2017. ,
Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas, Nat. Genet, vol.45, pp.295-298, 2013. ,
Germline SMARCB1 mutation and somatic NF2 mutations in familial multiple meningiomas, J. Med. Genet, vol.48, pp.93-97, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-00573999
, Hidden association of Cowden syndrome, PTEN mutation and meningioma frequency, Oncoscience, vol.149, 2016.
Families with BAP1-Tumor Predisposition Syndrome in The Netherlands: Path to Identification and a Proposal for Genetic Screening Guidelines, Cancers, vol.11, 2019. ,
Novel SUFU Frameshift Variant Leading to Meningioma in Three Generations in a Family with Gorlin Syndrome. Case Rep, Genet, vol.2019, pp.1-5, 2019. ,
High-grade meningiomas: biology and implications, Neurosurg. Focus, vol.44, p.2, 2018. ,
Molecular characteristics of meningiomas, J. Pathol. Transl. Med, vol.54, pp.45-63, 2020. ,
Role of Merlin/NF2 inactivation in tumor biology, Oncogene, vol.35, pp.537-548, 2016. ,
The Role of Merlin/NF2 Loss in Meningioma Biology, Cancers, vol.11, p.1633, 2019. ,
Genomic Analysis of Non-NF2 Meningiomas Reveals Mutations in TRAF7, KLF4, AKT1, and SMO, Science, vol.339, pp.1077-1080, 2013. ,
The Emerging Role of TRAF7 in Tumor Development: TRAF7 IN TUMOR DEVELOPMENT, J. Cell. Physiol, vol.232, pp.1233-1238, 2017. ,
TRAF molecules in cell signaling and in human diseases, J. Mol. Signal. 8, Art, vol.7, 2013. ,
KLF4 is a tumor suppressor in anaplastic meningioma stem-like cells and human meningiomas, J. Mol. Cell Biol, vol.9, pp.315-324, 2017. ,
PTEN and the PI3-Kinase Pathway in Cancer, Annu. Rev. Pathol, vol.4, pp.127-150, 2009. ,
The Hedgehog pathway: role in cell differentiation, polarity and proliferation, Arch. Toxicol, vol.89, pp.179-191, 2015. ,
SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas, Neuro-Oncol, vol.19, pp.345-351, 2017. ,
Genetic landscape of meningioma, Brain Tumor Pathol, vol.33, pp.237-247, 2016. ,
, Familial Syndromes Involving Meningiomas Provide Mechanistic Insight Into Sporadic Disease
, Neurosurgery, 2018.
Significantly high levels of ultraviolet-specific mutations in the smoothened gene in basal cell carcinomas from DNA repair-deficient xeroderma pigmentosum patients, Cancer Res, vol.62, pp.7186-7195, 2003. ,
TERT promoter mutation is associated with worse prognosis in WHO grade II and III meningiomas, J. Neurooncol, vol.139, pp.671-678, 2018. ,
Analysis of CDKN2A gene alterations in recurrent and non-recurrent meningioma, J. Neurooncol, vol.145, pp.449-459, 2019. ,
Alterations of the Tumor Suppressor Genes CDKN2A (p16INK4a), p14ARF, CDKN2B (p15INK4b), and CDKN2C (p18INK4c) in Atypical and Anaplastic Meningiomas, Am. J. Pathol, vol.159, pp.661-669, 2001. ,
Molecular alterations in meningiomas: Literature review, Clin. Neurol. Neurosurg, vol.176, pp.89-96, 2019. ,
Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas, Nat. Genet, vol.48, pp.1253-1259, 2016. ,
, Next generation sequencing identifies novel potential actionable mutations for grade I meningioma treatment, Histol. Histopathol, vol.1, 2019.
Molecular and translational advances in meningiomas, Neuro-Oncol, vol.21, pp.4-17, 2019. ,
A review of epigenetic and gene expression alterations associated with intracranial meningiomas, Neurosurg. Focus, vol.35, p.5, 2013. ,
Next-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification, Int. J. Mol. Sci, vol.18, 2017. ,
Review of Clinical Next-Generation Sequencing, Arch. Pathol. Lab. Med, vol.141, pp.1544-1557, 2017. ,
Detecting very low allele fraction variants using targeted DNA sequencing and a novel molecular barcode-aware variant caller, BMC Genomics, vol.18, p.5, 2017. ,
Towards Molecular Classification of Meningioma: Evolving Treatment and Diagnostic Paradigms, World Neurosurg, vol.119, pp.366-373, 2018. ,
, Recent Advances in Meningioma Immunogenetics. Front. Oncol, vol.9, p.1472, 2020.
Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations, Acta Neuropathol. (Berl.), vol.125, pp.351-358, 2013. ,
Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma, Neuro-Oncol, vol.18, pp.649-655, 2016. ,
Molecular progression in unusual recurrent non-pediatric intracranial clear cell meningioma, Curr. Oncol, vol.24, p.244, 2017. ,
Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1/2 activation and reduced time to tumor recurrence, Neuro-Oncol, vol.19, pp.1088-1096, 2017. ,
Correlations between genomic subgroup and clinical features in a cohort of more than 3000 meningiomas, J. Neurosurg, vol.1, issue.10, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02549269
Clinical potential of meningioma genomic insights: a practical review for neurosurgeons, Neurosurg. Focus, vol.44, p.10, 2018. ,
Advances in meningioma genetics: novel therapeutic opportunities, Nat. Rev. Neurol, vol.14, pp.106-115, 2018. ,
Germline SMARCE1 mutations predispose to both spinal and cranial clear cell meningiomas, J. Pathol, vol.234, pp.436-440, 2014. ,
Epigenetic changes underlie the aggressiveness of histologically benign meningiomas that recur, Hum. Pathol, vol.84, pp.105-114, 2019. ,
Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma, Acta Neuropathol. (Berl.), vol.133, pp.431-444, 2017. ,
DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management, Neuro-Oncol, vol.21, pp.901-910, 2019. ,
DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis, Lancet Oncol, vol.18, pp.682-694, 2017. ,
Quel avenir pour l'ADN tumoral circulant ? État des lieux et perspectives dans les cancers colorectaux, pulmonaires non à petites cellules et pancréatiques, Bull. Cancer (Paris), vol.103, pp.55-65, 2016. ,
Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer, Oncotarget, vol.7, 2016. ,
Integrating liquid biopsies into the management of cancer, Nat. Rev. Clin. Oncol, vol.14, pp.531-548, 2017. ,
Sensitive tumour detection and classification using plasma cell-free DNA methylomes, Nature, vol.563, pp.579-583, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01974928
Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma, Nat. Commun, vol.6, 2015. ,
De novo and secondary anaplastic meningiomas: a study of clinical and histomolecular prognostic factors, Neuro oncol, vol.20, pp.1113-1121, 2018. ,